Clearside Biomedical, Inc. (CLSDQ)
| Market Cap | 18.34M |
| Revenue (ttm) | 3.33M -56.8% |
| Net Income | -26.00M |
| EPS | -5.05 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133 |
| Open | 0.2490 |
| Previous Close | n/a |
| Day's Range | 0.2490 - 0.2490 |
| 52-Week Range | 0.0100 - 13.2000 |
| Beta | 1.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) ... [Read more]
Financial Performance
In 2024, Clearside Biomedical's revenue was $1.66 million, a decrease of -79.77% compared to the previous year's $8.23 million. Losses were -$34.35 million, 5.75% more than in 2023.
Financial StatementsNews
Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
NEW YORK--(BUSINESS WIRE)--Clearside Biomedical, Inc. (“Clearside” or the “Company”) today announced that it has completed its financial restructuring and emerged from Chapter 11. All conditions to th...
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations ...
Clearside Biomedical Quarterly report: Q3 2025
Clearside Biomedical has published its Q3 2025 quarterly earnings report on November 14, 2025.
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
- Presentations Highlight the Versatility of Clearside's SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -
Clearside Biomedical Quarterly report: Q2 2025
Clearside Biomedical has published its Q2 2025 quarterly earnings report on August 8, 2025.
Clearside Biomedical Proxy statement: Proxy Filing
Clearside Biomedical filed a proxy statement on August 4, 2025, providing details for shareholder voting and corporate governance matters.
Clearside Biomedical Proxy statement: Proxy Filing
Clearside Biomedical filed a proxy statement on July 25, 2025, providing details for shareholder voting and corporate governance matters.
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Micr...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase ...
Clearside Biomedical Transcript: Stifel 2025 Virtual Ophthalmology Forum
The session highlighted advances in suprachoroidal drug delivery, emphasizing the proprietary platform's growing acceptance and robust clinical data for CLS-AX in wet AMD. Flexible dosing, strong safety, and regulatory-aligned trial design position the product for phase III and commercialization, with funding discussions ongoing.
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexibl...
Clearside Biomedical Quarterly report: Q1 2025
Clearside Biomedical has published its Q1 2025 quarterly earnings report on May 14, 2025.
Clearside Biomedical Earnings release: Q1 2025
Clearside Biomedical released its Q1 2025 earnings on May 14, 2025, summarizing the period's financial results.
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Supra...
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the...
Clearside Biomedical Transcript: The Citizens JMP Life Sciences Conference 2025
Leaders in suprachoroidal drug delivery are advancing a phase III-ready asset for wet AMD, aiming for 3–6 month dosing intervals and leveraging strong phase II data. Phase III trials will align with real-world practice, with over 50% of patients expected to reach six-month intervals.
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical Proxy statement: Proxy Filing
Clearside Biomedical filed a proxy statement on April 18, 2025, providing details for shareholder voting and corporate governance matters.
Clearside Biomedical Proxy statement: Proxy Filing
Clearside Biomedical filed a proxy statement on April 18, 2025, providing details for shareholder voting and corporate governance matters.
Clearside Biomedical Proxy statement: Proxy Filing
Clearside Biomedical filed a proxy statement on April 8, 2025, providing details for shareholder voting and corporate governance matters.
Clearside Biomedical Transcript: 24th Annual Needham Virtual Healthcare Conference
The session highlighted advances in suprachoroidal drug delivery for retinal diseases, with a focus on the phase 3-ready CLS-AX for wet AMD and ongoing global partnerships. The company is optimizing trial design, expanding its pipeline, and actively seeking funding to support late-stage development.
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Clearside Biomedical Earnings Call Transcript: Q4 2024
Positive phase II-B results for CLS-AX in wet AMD led to FDA alignment on pivotal phase III trials. Cash reserves fund operations into Q4 2025, with additional funding sought for phase III. Multiple global partnerships and regulatory milestones expand the suprachoroidal platform.